Share This Post Erstellt amOktober 4, 2017durchThomas Eigentler You are here: Knowledge Base Melanoma: Systemic treatment Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study < Back 1445534 YQSWFA7Q items 1 default asc 1 1 http://www.hautkrebs-leitlinien.de/wp-content/plugins/zotpress/ Share This Post
Erstellt amOktober 4, 2017durchThomas Eigentler You are here: Knowledge Base Melanoma: Systemic treatment Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study < Back 1445534 YQSWFA7Q items 1 default asc 1 1 http://www.hautkrebs-leitlinien.de/wp-content/plugins/zotpress/
